Humboldt survivor on new documentary
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Province
an hour ago
- The Province
Summer McIntosh wins first gold medal at worlds in her quest for five
Published Jul 27, 2025 • Last updated 11 hours ago • 4 minute read From left to right: Silver medallist China's swimmer Li Bingjie, gold medallist Canada's swimmer Summer Mcintosh, and bronze medallist U.S.' swimmer Katie Ledecky celebrate on the podium of the women's 400m freestyle swimming event during the 2025 World Aquatics Championships in Singapore on July 27, 2025. Photo by MANAN VATSYAYANA / AFP via Getty Images SINGAPORE — For Summer McIntosh of Canada, it's one gold medal won at the swimming world championships with four to go. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors McIntosh is aiming to win five gold medals in individual events at the worlds in Singapore, and the first one came Sunday in the 400-metre freestyle on the first of eight days in the pool. Only legendary American Michael Phelps has ever won five individual medals in the worlds. He also did it at the Olympics. McIntosh won but did not break her own world record, winning in 3 minutes, 56.26 seconds. Li Bingjie of China took silver (3:58.21) with a late charge to leave American Katie Ledecky (3:58.49) with bronze. A year ago in the Olympics, Ledecky also took bronze in the 400. McIntosh was the silver medalist with gold for Australian Ariarne Titmus of Australia. Titmus is taking a year off and did not swim and has since lost her world record in the event to McIntosh. Essential reading for hockey fans who eat, sleep, Canucks, repeat. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. For Ledecky, a nine-time Olympic gold medalist, it was her 27th medal in the world championships in an astonishing career. She won her first Olympic gold in 2012 in London, and then started adding world championship medals beginning in Barcelona in 2013. About 25 minutes after winning the 400, McIntosh came back and qualified first in the 200 individual medley, clocking 2:07.39. American Alex Walsh was second in 2:08.49. That final is Monday. 'I've never done a double like that,' McIntosh said. 'I think the 400 free, at past world championships and Olympics, I haven't been at my best. And I haven't been where I wanted to be. So, to finally stand in the centre of the podium is promising for the rest of the meet.' The Canadian added: I think I'm at my best. I'm in the best shape of my life. So now I just have to act on that and put it into all my races.' This advertisement has not loaded yet, but your article continues below. The shock of the first day might have been Chinese 12-year-old Yu Zidi, who was the seventh fastest in qualifying and will swim in the final. Asked her reaction, she replied: 'Oh, I'm in,' unaware she had advanced. 'I will continue to work harder,' she added. 'I hope to find a breakthrough at these world championships and show my potential.' Asked for her reaction to the competition, she added. 'You can feel it's quite intense. I try not to think so much and just give it my all.' The 200 IM might not even be her best event with the Chinese likely quicker in the 400 IM and the 200 butterfly. Meanwhile, the United States is swimming with what appears to be a weakened team after officials acknowledged Sunday that some members of the team had come down with 'acute gastroenteritis' at a training camp in Thailand prior to arriving in Singapore. This advertisement has not loaded yet, but your article continues below. Nikki Warner, a spokeswoman for USA Swimming, would not say how many fell ill in Thailand. She cited health confidentiality rules. She said all American swimmers had traveled to Singapore. In the other early individual final Sunday, Lukas Martens of Germany won the men's 400 free in 3:42.35, edging Sam Short of Australia who was .02 behind. Bronze went to Kim Woomin of South Korea in 3:42.60. Martens is the defending Olympic champion and also holds the world record of 3:39.96. McIntosh, who won three gold medals a year ago at the Paris Olympics, holds the world record in the 400 free — 3:54.18. She will face off again with Ledecky in the 800 free later in the meet, probably the most anticipated race in Singapore. Though she holds the 400 free world record, McIntosh had failed to win gold in the event in the Olympics or previous world championships. This advertisement has not loaded yet, but your article continues below. McIntosh will also be after gold in the 200- and 400-individual medleys, and the 200 butterfly. Famed Olympian Michael Phelps is the only swimmer to have won five individual gold medals at a world championships. The other two gold medals Sunday were in the relays. The United States was the favourite in both and failed to win either. The Australian women took gold just ahead of the United States in the 4×100 freestyle relay. The Aussies clocked 3:30.60 with 3:31.04 for the US. The Netherlands took bronze in 3:33.89. On the men's side in the 4×100, Australia also took gold in 3:08.97. Italy took silver in 3:09.58 with bronze for the United States in 3:09.64. There were three other semifinal results on Sunday. Qin Haiyang of China took the 200 breaststroke in 58.24 with Paris Olympic champion Nicolo Martinenghi second in 58.62. The Italian was initially disqualified for moving on the blocks, but was later reinstated on appeal. Gretchen Walsh of the United States and Roos Vanotterdijk of Belgium tied in the 100 butterfly in 56.07, and Maxime Grousset of France took the men's 50 fly in 22.61. Check out our sports section for the latest news and analysis. Vancouver Canucks Sports Vancouver Whitecaps News BC Lions
National Post
2 hours ago
- National Post
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Article content – Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – Article content – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – Article content Article content – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – Article content – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – Article content SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Article content Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. Article content 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition.' Article content Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys ® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. Article content 'Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis,' said Matt Sause, CEO of Roche Diagnostics. 'Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families.' Article content Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Article content Pharmaceuticals Article content In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. Article content New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. Article content These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Article content Diagnostics Article content Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Article content Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys ® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys ® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Article content Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm – 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm – 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm – 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm – 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am – 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley Article content About trontinemab Article content Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. Article content The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. Article content About Roche in Alzheimer's Disease Article content With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. Article content About Genentech in Neuroscience Article content Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Article content Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. Article content Article content Article content Article content Article content
CBC
2 hours ago
- CBC
Abel Tesfaye returns to Toronto to kill The Weeknd
Social Sharing Unlike Taylor Swift's meteorite-like crash landing in the sweaty city of Toronto, there were no friendship bead-wearing police horses at The Weeknd's first showing in the Six. Instead, a more subdued air surrounded Rogers Centre as fans funnelled in: Low-key Starboy tracks warbling into the 30 C drippingly-wet air blanketing the stadium in the heart of The Weeknd's hometown. But that doesn't mean a lack of excitement, despite the weather. "God damn, it's hot," Canadian producer and DJ Kaytranada even exclaimed, towelling himself off onstage during a well-done if not earth-shattering opening. That was as sweltering fans at the first of four sold-out nights in the 50,000-seat venue braved the heat in requisitely dark clothes to match the R&B superstar infamously dark music. Just a day before, Mayor Olivia Chow dubbed the preceding days "The Weeknd weekend." That was because, she said, "Abel (The Weeknd) Tesfaye represents the best of our city." The Scarborough-raised artist also received a key to the city. And it was all just before audience members, eager to experience what is often still described as a once-in-a-lifetime concert experience, were uncharacteristically chatty with journalists — throwing themselves into on-camera interviews instead of waiting for the insistent coaxing of harried producers. "Everyone here, we are The Weeknd," a fan named Perry told CBC News. "He represents Canada." But as Tesfaye took the stage, the seemingly incongruous mix of emotions instantly made sense. Decked in a black robe encrusted with glittering gold rhinestones and a golden half-mask, you could see he embodied that caustic mix of the charismatic and subdued that, for anyone else, would not fit in the same person at the same time. As he has proven since releasing anonymous and unsettling dance-themed mixtapes in the 2010s all the way to this seemingly last tour under The Weeknd moniker, this is the space where Tesfaye thrives. While not retiring from music, he plans to no longer perform under the name he has become famous for. A return home Quickly barrelling through classic tracks The Abyss to Wake Me Up to After Hours, he was flanked by similarly masked, enrobed backup dancers — moving in unison around a slowly spinning golden statue of a giant, nude woman (imagine a female Oscars statuette, but with visible nipples). They stood beneath large gold rings, in front of a mocked up golden skyline of a crumbling city. Even Tesfaye's microphone was gold, a particularly heavy-handed metaphor that, early on, he stumbled chaotically toward. While roughly 30 women walked in sync around the statue and then behind to him, and as jets of fire shot up 20 feet into the air, Tesfaye held his hands up to the mic as if in prayer. None of them had to dance or even move much to earn the deafening applause that came next, as Tesfaye revealed the tiniest bit of his face, slightly peaking over the top of the mask. "Well that's a warm welcome home, isn't it?" he asked to another roar. It wasn't the last call out to his hometown. Later, he remarked the stadium is where he used to come to watch Blue Jays games "as a little baby," let out a long and extended "Toronto" in the middle of his track Sacrifice and managed to sneak both CN Tower and Rogers Centre references into São Paulo. But the focus was the gold, the ceremony and the performative reverence of it. The effect is impressive if eerie. A consummate musical professional with four Grammys under his belt and more Junos than anyone but Anne Murray, Tesfaye knows how to set a scene. He also knows how to sing, and — more than that — perform. He never failed to lead the tens of thousands of cheering attendants in song or just rapturous applause. It all gives the impression of some club-themed religious ceremony: A gigantic and enormously budgeted cultic worship service, except here the god is hedonism, sex and all the more outrageous scenes of Wolf of Wall Street. Of course, this is by design — both why The Weeknd can define himself as a generational sex symbol without gyrating or even revealing a sliver of his body under baggy robes and ostensibly why he's choosing to leave the schtick behind after this tour. In his shows and music, he's playing a club kid, fame-obsessed semi-satirical character invented way back in his debut mixtape House of Balloons days — itself a mask, Tesfaye explained in a 2013 Reddit AMA, he chose in order to hide his name and, by extension, himself. Vanity and nihilism In person, it all comes together like a magic trick. At a Weeknd concert, we're both sick of materialism, and sick of being sick of it. We're letting go of every inhibition, forgetting love, revelling in sex and giving up on self-control. It's all a statement about nihilism, you see. Or maybe, it's not. "It seems exorbitant when it all ends. A pointless, uncomfortable exercise from an artist who believes vanity means no stone of excess can be left unturned," music journalist Hanif Abdurraqib wrote of a 2013 Weeknd show in his book They Can't Kill Us Until They Kill Us. "The Weeknd tells the same tale: It's never about love, but then again, how can it be about anything but love, even if the love is just the love you have for your own ravenous desires." How much the separate entity of The Weeknd exists for Tesfaye to explore and mock his most self-destructive tendencies — instead of just revelling in them — isn't exactly clear. You would've been hard pressed to find any hints of displeasure from the seemingly ecstatic Tesfaye on Sunday. He hit hits old and new out of the park, and was grinning ear-to-ear as he held the microphone to nearly fainting fans, screaming out the ad libs of Out of Time. Still, it's perhaps a strange message to brand, as Chow did, the best of the city — and a strange one to have drawn as many barely five-foot middle-schoolers as Sunday's all-ages show did. At the same time, it's a theme that has offered diminishing returns. There was the 2022 Los Angeles concert in which Tesfaye infamously lost his voice due to stress. Then the ill-fated series The Idol, a Tesfaye-fronted series about the relentless pursuit of fame that was widely panned by critics and even The Weeknd himself. And then there was Hurry Up Tomorrow, the absurdly, incomprehensibly stupid filmic tie-in of his most recent album. Intended to further explore his falling-out-of-love with The Weeknd after the L.A. show, instead it only managed to compete with Megalopolis as the most offensively boring movie to premiere in the last 12 months. But perhaps these failures were because Tesfaye was performing to the wrong crowd, on the wrong stage. His messy, introspective and vague metaphors work better in song lyrics than dialogue; better sung in front of a stunning pyrotechnic flame and fireworks show than on a film screen. If Sunday's show proved anything, it was that. And even if on the inside he's done with The Weeknd, it proved he can certainly still fake it.
